About Celldex Therapeutics
Celldex Therapeutics (NASDAQ:CLDX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for cancer and other difficult-to-treat diseases. Drawing on a deep expertise in immunology, Celldex is pioneering a robust pipeline of potential therapies designed to enhance the body's natural defenses against disease. The company's projects span from early-stage research to phase 3 clinical trials, with key focuses on precision medicine and immune therapeutics. Through strategic collaborations and cutting-edge research, Celldex aims to improve patient outcomes and advance the field of medicine. Their objective is not only to deliver life-changing treatments to patients in need but also to lead the way in discovering and developing new pathways for treating cancer and immune-related diseases.
Snapshot
Operations
Products and/or services of Celldex Therapeutics
- CDX-0159: A monoclonal antibody targeting KIT for chronic inducible urticaria, currently in Phase 2 clinical trials.
- CDX-1140: An immune activating agonist targeting CD40, involved in Phase 1 trials for solid tumors and B-cell malignancies.
- CDX-527: A combination of an anti-PD-L1 and an anti-CD27 in one molecule, designed for various cancers, in Phase 1 trials.
- Glembatumumab vedotin: An antibody-drug conjugate targeting gpNMB for advanced melanoma and breast cancer, previously in clinical trials.
- Varlilumab: An agonist antibody targeting CD27 to activate the immune system against cancer, involved in clinical research.
- CDX-301: A recombinant human Flt3 ligand aimed at enhancing stem cell and immune restoration, used in various clinical settings.
Celldex Therapeutics executive team
- Mr. Anthony S. Marucci M.B.A.Founder, President, CEO & Director
- Dr. Tibor Keler Ph.D.Founder, Chief Scientific Officer & Executive VP
- Mr. Sam Martin CPASenior VP, CFO, Secretary & Treasurer
- Ms. Elizabeth CrowleyChief Product Development Officer & Senior VP
- Dr. Margo Heath-Chiozzi M.D.Senior Vice President of Regulatory Affairs
- Prof. Joseph P. Schlessinger Ph.D.Co-Founder & Member of Scientific Advisory Board
- Ms. Sarah CavanaughSenior Vice President of Corporate Affairs & Administration
- Mr. Freddy A. Jimenez Esq.Senior VP & General Counsel
- Dr. Ronald A. Pepin Ph.D.Chief Business Officer & Senior VP
- Dr. Diane C. Young M.D.Senior VP & Chief Medical Officer